Table 5 Non-relapse mortality—patient and transplant characteristics, and causes.

Age at HCT	Year of HCT	MF status at HCT	Donor type	Source of HCs	Conditioning regimen	Ex vivo TCD	In vivo TCD	GVHD prophylaxis	Survival (days after HCT)	Cause of death
17.4	2011	PMF	MSD	PB	Cy+Flu	No	ATG	CSA + MTX	13	Graft failure
1.7	2013	PMF	UD 5/6	CB	Treo+Flu+Thio	No	ATG	CSA + MMF	32	Graft failure
4.7	2003	PMF	MSD	PB	Bu+Cy	No	NA	missing	644	Graft failure
11.7	2000	PMF	UD^a	PB	TBI alone	Yes	NA	missing	62	acute GvHD
17.6	2005	PMF	UD 10/10	PB	Bu+Cy+Flu	Yes	No	CSA + MTX	102	acute GvHD
14.9	2007	PMF	UD (2/6; 3/6)	CB-double	Bu+Cy	No	No	CSA	109	acute GvHD

^aHLA not reported.
HCT haematopoietic cell transplantation, MF myelofibrosis, PMF primary myelofibrosis, HCs haematopoetic cells, MSD matched sibling donor, UD unrelated donor, PB peripheral blood, CB cord blood, Cy cyclophosphamide, Flu fludarabine, Treo treosulfan, Thio thiothepa, Bu busulfan, TBI total body irradiation, TCD T-cell depletion, GvHD graft versus host disease, ATG anti-thymocyte globuline, CSA cyclosporine A, MTX methotrexate, MFF mycophenolate mofetil.

Quick links

Search